SS-31 (Elamipretide) (30mg)
SS-31 (Elamipretide) targets the inner mitochondrial membrane, stabilizing cardiolipin and improving ATP production. Subcutaneous administration. Research sources report subcutaneous administration of 5 mg to 10 mg, once daily, increased gradually.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full SS-31 encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
SS-31 penetrates the mitochondrial membrane and binds to cardiolipin, stabilizing the respiratory complexes. It improves electron flow, increases ATP production, reduces ROS, and prevents mitochondrial dysfunction.
Quick Start
- Reconstitution: Add 3.0 mL bacteriostatic water → 10 mg/mL concentration.
- Range reported in research sources: 5 mg to 10 mg once daily, increased gradually.
- Easy measurement: At 10 mg/mL, 10 mg = 100 units (1.00 mL) on a U-100 syringe.
- Storage: −20 °C / 2–8 °C after reconstitution.
Ranges reported in research sources (3.0 mL = 10 mg/mL)
Route: Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 5 mg | 50 Units (0.50 mL) |
| Weeks 3–8 | 10 mg | 100 Units (1.00 mL) |
Research sources report subcutaneous administration once daily, increased gradually from 5 mg to 10 mg. The values are calculation examples from research sources, not validated human dosing.
Related compounds
Reconstitution Steps
- Draw 3.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial.
- Gently swirl.
- Refrigerate at 2–8 °C.
Protocol Overview
- Goal: Mitochondrial restoration, ATP enhancement, cardioprotection.
- Schedule reported in research sources: 5 mg to 10 mg subcutaneously, once daily, increased gradually over 8 weeks.
- Vials for the full schedule: about 17 vials of 30 mg (≈490 mg in total).
Dosing Protocol
- Weeks 1–2: 5 mg once daily.
- Weeks 3–8: 10 mg once daily.
- Cycle: 4–8 weeks.
- There is no validated human dosing — research context only.
- Break between cycles: After the cycle (4–8 weeks), a washout period of 4–6 weeks is recommended. SS-31 targets mitochondria — the pause helps prevent tolerance.
Washout & Cycle Restart
When can I restart?
After the cycle (4–8 weeks), a washout period of 4–6 weeks is recommended. SS-31 targets mitochondria — the pause helps prevent tolerance.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C.
- Reconstituted: 2–8 °C · within 3 weeks.
Important Notes
- Use sterile technique.
Potential Benefits & Side Effects
Potential Benefits:
- Enhanced mitochondrial function.
- Increased ATP production.
- Reduced oxidative stress.
- Cardioprotective effects.
Potential Side Effects:
- Mild injection site reaction.
- Generally very well-tolerated in clinical trials.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Renal safety under evaluation
Elamipretide is being evaluated for renal mitochondriopathies. Phase 3 in Barth syndrome did not meet primary endpoint.
📄 Stealth BioTherapeutics — Phase 3 ResultsReferences
- Journal of the American Heart Association — Elamipretide in heart failure
View Source - Aging Cell — SS-31 reverses mitochondrial aging
View Source
Recommended Supplements
NMN (Nicotinamide Mononucleotide)
CoQ10 (Ubiquinol)
Vitamin E (Mixed Tocopherols)
External Sources & Regulatory Status
Regulatory Approvals
Elamipretide · Barth syndrome / Mitochondrial disorders (2020)
Barth syndrome (NCT05168774)
FDA Breakthrough Therapy
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →